Biotech giant Regeneron Pharmaceuticals (REGN) said Monday that sales of its linchpin Eylea drug in the final quarter of 2022 were hurt by a shift to an off-label competitor. REGN stock plunged on the...
Tag: REGN
Stocks Are Ready for a Bounce Higher After S&P 500 Closes Above Bear Market
Text size Dreamstime The stock market came awfully close to finishing Friday in a bear market, at least 20% off its peak in early January. Many investors would like to see it get there so Wall Street ...